Navigation Links
Islet Sciences Announces Exclusive License Agreement with Winthrop University Hospital to Commercialize a Beta Cell Loss Measurement Technology in Diabetes
Date:9/10/2012

NEW YORK, Sept. 10, 2012 /PRNewswire/ -- Islet Sciences, Inc., (OTCBB: ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies in the field of transplantation therapy for patients with diabetes, today announced that it has exclusively licensed technology from Winthrop University Hospital. This technology is complimentary to the early Beta cell destruction diagnostic that Islet Sciences licensed last month.

"In the course of research conducted under Winthrop University Hospital, Dr. Eitan Akirav and his colleagues at Winthrop have developed a technology entitled Method for Using Probe Based PCR Detection to Measure the Levels of Circulating Demethylated Beta Cell Derived DNA as a Measure of Beta Cell Loss in Diabetes," stated John Steel, Chairman and CEO of Islet Sciences. "We are pleased to bring this groundbreaking technology to the next level as we look to commercialize it to benefit the growing worldwide diabetic community. There has been a long-felt need for a method capable of accurately evaluating Beta cell death so as to improve disease diagnosis, allow for disease staging, and provide a better evaluation of clinical treatment efficacy. The method can identify Beta cell death before the onset of hyperglycemia and soon after the onset of T1D."

"The method provides a noninvasive approach for detecting Beta cell death in vivo that may be used to track the progression of diabetes and guide its treatment," said Dr. Eitan Akirav, Research Scientist at Winthrop University Hospital. "I am excited to work with Islet Sciences to bring this technology to market which clearly has so much potential. The method uses a stepwise detection and analysis of Beta cell and non-Beta cell derived insulin DNA. The key principle behind the method is the existence of unique DNA methylation patterns in the Beta cells that are absent from other cells in the body."

Alan M. Jacobson, MD, Chief Research Officer, Director of the Diabetes, Obesity and Cardiometabolic Research Center and Senior Scientist, Winthrop University Hospital Research Institute commented, "We look forward to working with Islet Sciences as they invest in this discovery and develop it into a valuable new tool for treating this life altering disease."

About Islet Sciences, Inc.
Islet Sciences is a development-stage biotechnology company with patented technologies focused on transplantation therapy for people with insulin-dependent diabetes.  The Company's transplantation technology includes methods for the culturing, isolation, maturation, and immunoprotection (microencapsulation) of islet cells. The Company's mission includes the introduction of commercial products with applications to cell-based replacement therapy in the healthcare marketplace. www.isletsciences.com

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements for Islet Sciences reflect current expectations, as of the date of this press release, and involve certain risks and uncertainties.   Actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors.  Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the risks described in the Islet Science's reports filed with the Securities and Exchange Commission.  The companies' further development is highly dependent on future medical and research developments and market acceptance, which is outside their control.

Investor Contact:
Jeff Ramson
ProActive Capital Resources Group
(646) 863-6893
jramson@proactivecrg.com


'/>"/>
SOURCE Islet Sciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Islet Sciences, Inc. Selects NeoStems Manufacturing Subsidiary Progenitor Cell Therapy for Product Manufacturing
2. Islet Sciences Announces DiaKine Therapeutics Novel Diabetes, Atherosclerosis Drugs Receives European Patent Protection
3. Islet Sciences Announces Receipt of $2.1 Million in Grant Support of Technology
4. Islet Sciences Names Richard A. Franco, Sr. to its Board of Directors
5. Garage Start-ups Now Possible in Life Sciences Industry
6. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
7. DiaTech Life Sciences Announces Medical Advisory Board
8. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
9. Coronado Biosciences to Present at the Oppenheimer 22nd Annual Healthcare Conference
10. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
11. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... WARSAW, Ind. , May 23, 2016 Zimmer ... in musculoskeletal healthcare, today announced that its Board of Directors ... stockholders for the second quarter of 2016. ... on or about July 29, 2016 to stockholders of record ... Future declarations of dividends are subject to approval of the ...
(Date:5/23/2016)... ... 23, 2016 , ... Foresight Institute , a leading ... for the 2015 Foresight Institute Feynman Prizes. , These prestigious prizes, named ... for experiment and the other for theory in nanotechnology. Prof. Markus J. Buehler, ...
(Date:5/20/2016)... ... 20, 2016 , ... Korean researchers say Manumycin A triggers apoptosis, or natural ... to treat the disease. Surviving Mesothelioma has just posted an article on the new ... institutions based their mesothelioma study on the fact the Manumycin A, a derivative of ...
(Date:5/19/2016)... , May 19, 2016 There ... fully recover given the relentless pressures in pricing and ... in the investors circle though - numerous opportunities are ... of today,s session, ActiveWallSt.com,s presents four names in this ... Vitae Pharmaceuticals Inc. (NASDAQ: VTAE ), Anthera ...
Breaking Biology Technology:
(Date:3/23/2016)... WAKEFIELD, Massachusetts , March 23, 2016 ... kombiniert im Interesse erhöhter Sicherheit Gesichts- und ... Xura, Inc. (NASDAQ: MESG ... heute bekannt, dass das Unternehmen mit SpeechPro ... insbesondere aus der Finanzdienstleistungsbranche, wird die Möglichkeit ...
(Date:3/21/2016)... , March 22, 2016 ... with passcodes for superior security   ... leading provider of secure digital communications services, today announced ... technology and offer enterprise customers, particularly those in the ... recognition and voice authentication within a mobile app, alongside, ...
(Date:3/15/2016)... --> --> ... Research "Digital Door Lock Systems Market - Global Industry Analysis, ... global digital door lock systems market in terms of revenue ... forecast to grow at a CAGR of 31.8% during the ... enterprises (MSMEs) across the world and high industrial activity driving ...
Breaking Biology News(10 mins):